NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $280 | -23.9% | 14,577 | +0.7% | 0.00% | – |
| Q2 2023 | $368 | -44.7% | 14,476 | -21.4% | 0.00% | -100.0% |
| Q1 2023 | $665 | -32.8% | 18,406 | -26.4% | 0.00% | 0.0% |
| Q4 2022 | $990 | -99.9% | 24,997 | +0.0% | 0.00% | -50.0% |
| Q3 2022 | $1,164,000 | -30.8% | 24,989 | -34.9% | 0.00% | 0.0% |
| Q2 2022 | $1,681,000 | -7.1% | 38,363 | +53.4% | 0.00% | 0.0% |
| Q1 2022 | $1,809,000 | -10.7% | 25,007 | +0.0% | 0.00% | 0.0% |
| Q4 2021 | $2,026,000 | -30.5% | 24,995 | -0.3% | 0.00% | -33.3% |
| Q3 2021 | $2,917,000 | -41.3% | 25,064 | -16.4% | 0.00% | -40.0% |
| Q2 2021 | $4,968,000 | +17.9% | 29,966 | -0.8% | 0.01% | 0.0% |
| Q1 2021 | $4,213,000 | -45.1% | 30,200 | -31.9% | 0.01% | -44.4% |
| Q4 2020 | $7,678,000 | +20.7% | 44,354 | -2.8% | 0.01% | +12.5% |
| Q3 2020 | $6,360,000 | +23.0% | 45,654 | +5.5% | 0.01% | +14.3% |
| Q2 2020 | $5,169,000 | +40.2% | 43,267 | +17.3% | 0.01% | +16.7% |
| Q1 2020 | $3,687,000 | +15.8% | 36,875 | +36.1% | 0.01% | +50.0% |
| Q4 2019 | $3,185,000 | +15.8% | 27,100 | -15.3% | 0.00% | +33.3% |
| Q3 2019 | $2,751,000 | +19.8% | 32,000 | -9.7% | 0.00% | 0.0% |
| Q2 2019 | $2,297,000 | -4.5% | 35,435 | -7.9% | 0.00% | 0.0% |
| Q1 2019 | $2,406,000 | +76.8% | 38,491 | +10.0% | 0.00% | +50.0% |
| Q4 2018 | $1,361,000 | -29.6% | 34,987 | +3.2% | 0.00% | 0.0% |
| Q3 2018 | $1,932,000 | -79.1% | 33,900 | -70.7% | 0.00% | -83.3% |
| Q2 2018 | $9,229,000 | -13.0% | 115,577 | -5.6% | 0.01% | -7.7% |
| Q1 2018 | $10,611,000 | +33.0% | 122,434 | +5.9% | 0.01% | +30.0% |
| Q4 2017 | $7,981,000 | -25.7% | 115,599 | -2.2% | 0.01% | -28.6% |
| Q3 2017 | $10,746,000 | +38.2% | 118,249 | +13.2% | 0.01% | +40.0% |
| Q2 2017 | $7,778,000 | -18.2% | 104,495 | +3.0% | 0.01% | -23.1% |
| Q1 2017 | $9,507,000 | +33.5% | 101,467 | +3.5% | 0.01% | +30.0% |
| Q4 2016 | $7,121,000 | -45.7% | 98,001 | -22.0% | 0.01% | -47.4% |
| Q3 2016 | $13,113,000 | +38.8% | 125,615 | -1.9% | 0.02% | +35.7% |
| Q2 2016 | $9,449,000 | +57.4% | 128,100 | +20.1% | 0.01% | +55.6% |
| Q1 2016 | $6,002,000 | +13.4% | 106,692 | +36.0% | 0.01% | +12.5% |
| Q4 2015 | $5,295,000 | +128.1% | 78,439 | +56.7% | 0.01% | +100.0% |
| Q3 2015 | $2,321,000 | +229.7% | 50,043 | +282.2% | 0.00% | +300.0% |
| Q2 2015 | $704,000 | – | 13,093 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |